Stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer - Acute toxicity and patient-reported outcomes in the prospective, multicenter SMILE phase II trial

CONCLUSION: Daily online-adaptive MRgSBRT for localized prostate cancer resulted in an excellent overall toxicity profile without any major negative impact on quality of life.PMID:38586081 | PMC:PMC10998039 | DOI:10.1016/j.ctro.2024.100771

Source: Clinical Prostate Cancer - April 8, 2024 Category: Cancer & Oncology Authors: C A Fink J Ristau C Buchele S Kl üter J Liermann P Hoegen-Sa ßmannshausen E Sandrini A Lentz-Hommertgen L Baumann N Andratschke M Baumgartl M Li M Reiner S Corradini J H örner-Rieber D Bonekamp H-P Schlemmer C Belka M Guckenberger J Debus S A Koerber Source Type: research